Feasibility of a First-Line Physical Activity Intervention After Stroke
Launched by UNIVERSITY OF MINNESOTA · Nov 5, 2024
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Stroke diagnosis confirmed by imaging
- • Admitted to Fairview Health System (Minnesota) at the time of study enrollment or discharged to a community-based setting from Fairview Health System within 10 days before study enrollment
- • Able and willing to participate fully in the study and provide informed consent or proxy consent with participant assent
- Exclusion Criteria:
- • Discharge anticipated to a transitional care unit, skilled nursing facility, or other non-community-based care setting
- • Severe cognitive or communication impairments (inability to respond accurately to complete study screening questions or to provide informed consent or assent
- • Comorbid neurological disorder (Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, myasthenia gravis, dementia, Alzheimer's disease, Huntington's disease, glioblastoma, spinal cord injury, cerebral palsy)
- • Comorbid cancer, currently undergoing chemotherapy or radiation treatment
- • Received inpatient treatment or was hospitalized for psychiatric condition and/or alcohol or substance abuse within the past 12 months
- • Current diagnosis of a terimnal illness and/or receiving hospice care
- • History of allergic reaction to adhesives that precludes the use of an adhesive necessary for adherence to activPAL measurement
- • Inability to speak, read, or understand English
- • Concurrent participation in another rehabilitation intervention research study
- • Resides more than 50 miles outside of the Twin Cities metropolitan area
- • Investigator discretion for safety or adherence reasons
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Emily Kringle, PhD, OTR/L
Principal Investigator
University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported